Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Jacques Tootight who wrote (658)	3/22/1998 3:32:00 PM
From: Jerry Olson	Read Replies (2) \| Respond to of 9523

RC Do you have a date for that Board of Directors meeting???? Kid i'm 56 been trading the market 25 years<g>. On most option plays i look for a double...you do the same...don't be afraid to "sell too early"...a profit is a profit... On PFE it's just too strong right now with all the other things too...

To: Jacques Tootight who wrote (658)	3/22/1998 3:34:00 PM
From: Jerry Olson	Respond to of 9523

Thread check it out!!!!!!!!!!! Sunday March 22, 1:54 pm Eastern Time Avalon Research outlines buys and sells -Barron's NEW YORK, March 22 (Reuters) - Avalon Research Group founder Mike Margolies, who sells research to 100 big money managers, outlined his recent buy and sell recommendations in an interview with Barron's. The Boca Raton, Fla., firm, which relies on a network of industry sources, is still bulllish on pharmaceutical company Pfizer Inc. (PFE - news) because of its promising new product line, including its Viagra impotence drug, Barron's said. Other buy recommendations include biotech firm Creative Biomolecules Inc. (CBMI - news) and Monsanto Co. (MTC - news) spinoff Solutia Inc (SOI - news). The firm recommends selling telecommunications equipment maker Ciena Corp. (CIEN - news), which recently plunged after it warned its big customer WorldCom Inc. (WCOM - news) was going to cut orders. The firm will soon face competition from other telecommunications equipment makers, Margolies said, according to Barron's. Other sell recommendations include Advanced Tissue Sciences Inc. (ATIS - news), which makes bioengineered human tissue products, and North American Vaccine (NVX - news), which is developing a combined diphtheria, tetanus and pertussis prevention shot. ((New York Newsdesk Tel (212) 859-1610, Fax (212) 859-1717) More Quotes and News: Advanced Tissue Sciences Inc (Nasdaq:ATIS - news) Ciena Corp (Nasdaq:CIEN - news) Creative Biomolecules Inc (Nasdaq:CBMI - news) Monsanto Co (NYSE:MTC - news) North American Vaccine Inc (AMEX:NVX - news) Pfizer Inc (NYSE:PFE - news) Solutia Inc (NYSE:SOI - news) Worldcom Inc (Nasdaq:WCOM - news) Related News Categories: US Market News, health Help Copyright c 1998 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon See our Important Disclaimers and Legal Information. Questions or Com